Bydureon BCise autoinjector approved

AstraZeneca received FDA approval on Oct. 20, 2017 for Bydureon BCise, a single-dose autoinjector form of exenatide extended-release, the once-weekly GLP-1 receptor agonist used in type 2 diabetes. The approval was granted under new drug application (NDA) 209210.

The new device was aimed squarely at a usability problem. The original weekly exenatide product required patients to combine a dry powder with a liquid diluent themselves before injecting, a multi-step mixing routine that many people found awkward and time-consuming compared with the pen injectors used for other diabetes drugs. The BCise autoinjector was designed to simplify that process into a single-dose device.

Several specifics are not established here. The exact labeled dose, needle size, injection-site options, storage requirements and the clinical data package that supported NDA 209210 have not been detailed, and the US list price and launch date for the autoinjector have not been disclosed. Readers looking for those details would need to consult the product's FDA-approved labeling and the prescribing information in effect today.

Why the device matters, not just the molecule

In the GLP-1 category, delivery has often been as commercially important as the active ingredient. A weekly injection that is hard to prepare competes poorly against one that comes ready to use, even when the underlying medicine is the same. That is the logic behind the BCise version: keep exenatide extended-release, change how it is delivered.

It is worth noting that exenatide is an older GLP-1 molecule than semaglutide (sold as Ozempic, Wegovy and Rybelsus) or tirzepatide (Mounjaro and Zepbound), and this 2017 action was an approval of a new presentation rather than a new drug. How the autoinjector performed in the market against later weekly products has not been reported here.

Why it matters for patients

For people who use or are considering an injectable GLP-1, the practical takeaway is that the same molecule can come in very different devices, and the device shapes the day-to-day experience: how many steps are involved, how much room for error there is, and how easy it is to keep a weekly routine. Approval of a single-dose autoinjector version of weekly exenatide added an option that removed the at-home mixing step tied to the earlier formulation.

Device differences can also affect cost and access in ways that are separate from the medicine itself. Insurance formularies typically list specific products and presentations, so a new autoinjector version may or may not be covered on the same terms as the original. Whether coverage shifted after this approval has not been reported.

A broader point applies to any brand in this category: approval is not permanent. The FDA routinely withdraws approval of NDAs when manufacturers tell the agency a product is no longer marketed and ask for the application to be withdrawn. In one such action, the agency withdrew approval of 39 NDAs from multiple applicants, with the withdrawals effective Sept. 3, 2025 ^[1]. Those requests are handled under 21 CFR 314.150(c), and by asking for withdrawal the companies waive their right to a hearing ^[1]. Importantly, withdrawal under that provision is "without prejudice to refiling," meaning a company can seek approval again later ^[1].

That notice, published Aug. 4, 2025 at 90 FR 36440 under Docket No. FDA-2025-N-2422, was followed by a correction notice on Oct. 3, 2025 ^[1]. It covered older products such as dexamethasone and doxepin formulations rather than GLP-1 drugs ^[1], but it illustrates the mechanism: a discontinued product's approval can be formally retired at the sponsor's request, which is why the current status of any specific presentation is worth checking rather than assumed.

What happens next

The key dated milestones on the record are the Oct. 20, 2017 approval of NDA 209210 for the Bydureon BCise autoinjector and, separately, the FDA's Sept. 3, 2025 effective date for the batch of 39 NDA withdrawals described in its Aug. 4, 2025 notice, later corrected on Oct. 3, 2025 ^[1]. Any subsequent labeling changes, supply decisions or marketing status changes for the exenatide autoinjector have not been disclosed.